MiR-7 also activates NRF2 by targeting KEAP1 expression in human SH-SY5Y neuroblastoma cells, resulting in increased levels of the reduced form of GSH, indicative of OS mitigation [182]. The gene discussed is KEAP1; the disease is neuroblastoma.